Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution

被引:21
作者
Nguyen, Thuy [1 ]
German, Nadezhda [1 ]
Decker, Ann M. [1 ]
Langston, Tiffany L. [1 ]
Gamage, Thomas F. [1 ]
Farquhar, Charlotte E. [1 ]
Li, Jun-Xu [2 ]
Wiley, Jenny L. [1 ]
Thomas, Brian F. [1 ]
Zhang, Yanan [1 ]
机构
[1] Res Triangle Inst, Res Triangle Pk, NC 27709 USA
[2] Univ Buffalo State Univ New York, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
ANTAGONIST; COCAINE; RELAPSE; REINSTATEMENT; MECHANISM; FLUORINE; SEEKING;
D O I
10.1021/acs.jmedchem.7b00707
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Allosteric modulators of the cannabinoid CB1 receptor have recently been reported as an alternative approach to modulate the CB1 receptor for therapeutic benefits. In this study, we report the design and synthesis of a series of diarylureas derived from PSNCBAM-1 (2). Similar to 2, these diarylureas dose-dependently inhibited CPSS,940-induced intracellular calcium mobilization and [S-35]GTP-gamma-S binding while enhancing [H-3]CPSS,940 binding to the CB1 receptor. Structure activity relationship studies revealed that the pyridinyl ring of 2 could be replaced by other aromatic rings and the pyrrolidinyl ring is not required for CB1 allosteric modulation. 34 (RTICBM-74) had similar potencies as 2 in all in vitro assays but showed significantly improved metabolic stability to rat liver microsomes. More importantly, 34 was, more effective than 2 in attenuating the reinstatement of extinguished cocaine-seeking behavior in rats, demonstrating the potential of this diarylurea series as promising candidates for the development of relapse treatment of cocaine addiction.
引用
收藏
页码:7410 / 7424
页数:15
相关论文
共 31 条
[1]   CB1 Receptor Allosteric Modulators Display Both Agonist and Signaling Pathway Specificity [J].
Baillie, Gemma L. ;
Horswill, James G. ;
Anavi-Goffer, Sharon ;
Reggio, Patricia H. ;
Bolognini, Daniele ;
Abood, Mary E. ;
McAllister, Sean ;
Strange, Phillip G. ;
Stephens, Gary J. ;
Pertwee, Roger G. ;
Ross, Ruth A. .
MOLECULAR PHARMACOLOGY, 2013, 83 (02) :322-338
[2]   Fluorine in medicinal chemistry [J].
Böhm, HJ ;
Banner, D ;
Bendels, S ;
Kansy, M ;
Kuhn, B ;
Müller, K ;
Obst-Sander, U ;
Stahl, M .
CHEMBIOCHEM, 2004, 5 (05) :637-643
[3]   Rimonabant: The first therapeutically relevant cannabinoid antagonist [J].
Carai, MAM ;
Colombo, G ;
Gessa, GL .
LIFE SCIENCES, 2005, 77 (19) :2339-2350
[4]  
Caroti E, 2013, RIV PSICHIATR, V48, P375, DOI 10.1708/1356.15064
[5]   A cannabinoid mechanism in relapse to cocaine seeking [J].
De Vries, TJ ;
Shaham, Y ;
Homberg, JR ;
Crombag, H ;
Schuurman, K ;
Dieben, J ;
Vanderschuren, LJMJ ;
Schoffelmeer, ANM .
NATURE MEDICINE, 2001, 7 (10) :1151-1154
[6]  
Di Marzo V, 2000, CURR PHARM DESIGN, V6, P1361
[7]   Behavioral effects of the cannabinoid CB1 receptor allosteric modulator ORG27569 in rats [J].
Ding, Yuanyuan ;
Qiu, Yanyan ;
Jing, Li ;
Thorn, David A. ;
Zhang, Yanan ;
Li, Jun-Xu .
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2014, 2 (06)
[8]   Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity [J].
Dorr, P ;
Westby, M ;
Dobbs, S ;
Griffin, P ;
Irvine, B ;
Macartney, M ;
Mori, J ;
Rickett, G ;
Smith-Burchnell, C ;
Napier, C ;
Webster, R ;
Armour, D ;
Price, D ;
Stammen, B ;
Wood, A ;
Perros, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (11) :4721-4732
[9]   Cannabinoid CB1 antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats [J].
Fattore, L ;
Spano, S ;
Cossu, G ;
Deiana, S ;
Fadda, P ;
Fratta, W .
NEUROPHARMACOLOGY, 2005, 48 (08) :1097-1104
[10]   An endocannabinoid mechanism in relapse to drug seeking: A review of animal studies and clinical perspectives [J].
Fattore, Liana ;
Spano, M. Sabrina ;
Deiana, Serena ;
Melis, Valeria ;
Cossu, Gregorio ;
Fadda, Paola ;
Fratta, Walter .
BRAIN RESEARCH REVIEWS, 2007, 53 (01) :1-16